Renal infarction in systemic lupus with antiphospholipid syndrome: Role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al;Infarctus rénaux au cours d'un lupus avec syndrome des antiphospholipides: implication du sevrage en hydroxychloroquine ? Commentaire à propos de l'article de Szymezak et al.

Revue de Medecine Interne

Volumn 32, Issue 4, 2011, Pages 261-262

  Zenone, T ^a   Knefati, Y ^a  

^a CENTRE HOSPITALIER DE VALENCE   (France)

Author keywords

Hydroxychloroquine; Renal infarct

Indexed keywords

HYDROXYCHLOROQUINE;

ANTIPHOSPHOLIPID SYNDROME; COMORBIDITY; DRUG WITHDRAWAL; KIDNEY INFARCTION; LETTER; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; HYDROXYCHLOROQUINE; INFARCTION; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 79953324314     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2011.01.006     Document Type: Letter

References (4)

1. Szymezak J., Ankri A., Fischer A.M., Darnige L. Hydroxychloroquine: une nouvelle approche thérapeutique des manifestations thrombotiques du syndrome des antiphospholipides. Rev Med Interne 2010, 31:854-857.
2. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2010 ; doi:10.1007/s11926-010-0141-y.
3. Jung H., Bobba R., Su J., Shariati-Sarabi Z., Gladman D.D., Urowitz M., et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010, 62:863-868.
4. A randomized study of the effect of withdrawing hydroxychloroquinesulfate in systemic lupus erythematosus. N Engl J Med 1991, 324:150-154. The canadian hydroxychloroquine study group.